Immutep (ASX:IMM) share price jumps 5% on Chinese patent grant

Immutep shares make their walk northwards after a patent was granted on Friday.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immutep Ltd (ASX: IMM) share price has stepped into the green from the opening of trade on Friday.

Immutep shares are on the move as the company announced it had been granted a Chinese patent on one of its antibody molecules.

Let's investigate further.

A bit of background to set the scene

Immutep advised that Chinese health authorities had granted the company a new patent on Friday. The company was awarded the approval to develop its "LAG-3 immunotherapeutic products".

In humans, the "lymphocyte activation gene-3", also known as LAG-3, acts like an "immune checkpoint" in the internal highways of our body. That means it is important to regulate our immune system so that it only destroys the foreign and nasty cells inside of us. And not our own.

Immutep has developed a "therapeutic antagonist antibody" called IMP701 to target this LAG-3 molecule. It claims that IMP701 "removes the brakes" that prevent our immune system from "responding to and killing cancer cells".

To achieve this result in humans, Immutep has teamed up with global healthcare giant Novartis AG to further develop the IMP701 antibody.

Together, the pair have created a compound called LAG525, a "humanised form" of IMP701 which is currently being investigated in three separate clinical trials.

What did Immutep announce?

From today's announcement, the patent is particularly "directed to" LAG525. This covers how the antibody is made, and its application in treating illnesses.

In fact, the patent was granted under the specific heading of "Antibody molecules to LAG-3 and uses thereof" from the Chinese Patent Office, to demonstrate this point.

As such, the approval follows the "corresponding" Australian, US, European and Japanese patents that have been previously granted on this molecule from 2018 to 2020.

Obtaining patent approval effectively protects the company's compound, and prevents others from making similar copies. Therefore, it stands to reason that Immutep has gained some competitive advantage with the grant of this patent.

Investors seem to think so too, driving the Immutep share price around 5% higher from the market open on Friday.

Immutep shares are now exchanging hands at 52 cents apiece, down from their intraday high of 54 cents each.

Immutep share price snapshot

The Immutep share price has posted a year to date gain of 27%. This extends the previous 12 month's gain of 171%.

Immutep shares have also climbed around 9% in the green over the last month. Moreover, in the last week, the Immutep share price is up 16%.

These results have outpaced the S&P/ASX 200 index (ASX: XJO)'s return of about 25% over the past year.

Should you invest $1,000 in Immutep Limited right now?

Before you buy Immutep Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Immutep Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a horrid end to the trading week this Friday.

Read more »

Three people jumping cheerfully in clear sunny weather.
Share Gainers

3 ASX 200 stocks rocketing higher this week even as the market dives

These three ASX 200 stocks are shrugging off the wider market sell-off this week to leap higher.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Share Gainers

Why Insignia, Meteoric Resources, Qantas, and West African shares are pushing higher today

These shares are avoiding the market selloff today.

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX suffered another fall this Thursday.

Read more »

rising gold share price represented by a green arrow on piles of gold block
Gold

Guess which ASX 200 gold stock just rocketed 11% on surging full-year profits

Shares in the ASX 200 gold miner have now surged 112% in a year. But why?

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Droneshield, Magellan, Pointsbet, and West African shares are racing higher today

Let's see why investors are buying these shares on Thursday.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a very woeful Wednesday indeed for investors today.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today

These shares are having a good time on hump day. But why?

Read more »